# Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)

> **NCT05712902** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Dizal Pharmaceuticals** · enrollment: 104 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Sunvozertinib

## Key facts

- **NCT ID:** NCT05712902
- **Lead sponsor:** Dizal Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-07-19
- **Primary completion:** 2022-10-17
- **Final completion:** 2025-12-31
- **Target enrollment:** 104 (ACTUAL)
- **Last updated:** 2024-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05712902

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05712902, "Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05712902. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*